Cytokinetics Total Debt vs Debt Current Analysis

CYTK
 Stock
  

USD 50.57  0.24  0.47%   

Cytokinetics financial indicator trend analysis is way more than just evaluating Cytokinetics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cytokinetics is a good investment. Please check the relationship between Cytokinetics Total Debt and its Debt Current accounts. Continue to Trending Equities.

Total Debt vs Debt Current

Total Debt vs Debt Current Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cytokinetics Total Debt account and Debt Current. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Cytokinetics' Total Debt and Debt Current is 0.94. Overlapping area represents the amount of variation of Total Debt that can explain the historical movement of Debt Current in the same time period over historical financial statements of Cytokinetics, assuming nothing else is changed. The correlation between historical values of Cytokinetics' Total Debt and Debt Current is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Debt of Cytokinetics are associated (or correlated) with its Debt Current. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Debt Current has no effect on the direction of Total Debt i.e., Cytokinetics' Total Debt and Debt Current go up and down completely randomly.

Correlation Coefficient

0.94
Relationship DirectionPositive 
Relationship StrengthVery Strong

Total Debt

Total Debt of Cytokinetics is a combination of both Cytokinetics short-term and long-term liabilities. Short-term debts are those that must be paid back within a year. This type of debt applies to things like lines of credit or short-term term bonds. Long-term debt of Cytokinetics includes liability that must be paid off in more than a year. This typically includes large senior debts like mortgages, bonds, as well as business loans or leases. A component of Total Liabilities representing the total amount of current and non-current debt owed. Includes secured and unsecured bonds issued; commercial paper; notes payable; credit facilities; lines of credit; capital lease obligations; operating lease obligations; and convertible notes.

Debt Current

The current portion of Total Debt; reported if the company operates a classified balance sheet that segments current and non-current liabilities.
Most indicators from Cytokinetics fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cytokinetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Continue to Trending Equities.Cytokinetics Selling General and Administrative Expense is increasing as compared to previous years. The last year's value of Selling General and Administrative Expense was reported at 96.8 Million. The current Issuance Purchase of Equity Shares is estimated to increase to about 345.2 M, while Enterprise Value over EBITDA is projected to decrease to (20.81) .
 2019 2020 2021 2022 (projected)
Revenues USD26.87 M55.83 M70.43 M59.29 M
Revenues26.87 M55.83 M70.43 M59.29 M

Cytokinetics fundamental ratios Correlations

0.960.910.810.990.540.920.980.920.690.890.850.760.970.860.890.850.961.00.82
0.960.970.910.980.650.980.980.980.80.850.940.870.980.950.930.941.00.970.74
0.910.970.980.950.720.970.920.970.840.860.990.950.950.980.910.980.970.920.73
0.810.910.980.860.770.930.840.930.860.80.990.980.880.980.870.980.910.830.65
0.990.980.950.860.590.960.980.960.740.880.90.810.980.910.910.890.981.00.8
0.540.650.720.770.590.60.580.590.460.680.680.680.590.690.740.680.650.560.34
0.920.980.970.930.960.60.941.00.870.780.970.920.960.980.880.970.980.930.73
0.980.980.920.840.980.580.940.930.730.860.870.780.970.880.930.860.980.980.82
0.920.980.970.930.960.591.00.930.870.770.970.920.960.980.870.970.980.930.72
0.690.80.840.860.740.460.870.730.870.480.890.890.830.910.690.920.80.70.57
0.890.850.860.80.880.680.780.860.770.480.780.710.820.760.870.730.850.90.79
0.850.940.990.990.90.680.970.870.970.890.780.990.920.990.850.990.940.860.66
0.760.870.950.980.810.680.920.780.920.890.710.990.850.970.790.980.870.770.57
0.970.980.950.880.980.590.960.970.960.830.820.920.850.940.890.930.980.970.77
0.860.950.980.980.910.690.980.880.980.910.760.990.970.940.871.00.950.870.66
0.890.930.910.870.910.740.880.930.870.690.870.850.790.890.870.840.930.90.75
0.850.940.980.980.890.680.970.860.970.920.730.990.980.931.00.840.940.860.65
0.961.00.970.910.980.650.980.980.980.80.850.940.870.980.950.930.940.970.74
1.00.970.920.831.00.560.930.980.930.70.90.860.770.970.870.90.860.970.82
0.820.740.730.650.80.340.730.820.720.570.790.660.570.770.660.750.650.740.82
Click cells to compare fundamentals

Cytokinetics Account Relationship Matchups

Cytokinetics fundamental ratios Accounts

201720182019202020212022 (projected)
Accounts Payable5.25 M3.76 M8.16 M8.05 M21.09 M22.75 M
Accumulated Other Comprehensive Income137 K343 K500 K679 K(869 K)(891.87 K)
Total Assets294.81 M211.18 M289.81 M533.8 M841.32 M907.74 M
Current Assets274.3 M207.67 M233.75 M474.22 M535.67 M577.96 M
Assets Non Current20.52 M3.5 M56.06 M59.58 M305.65 M329.78 M
Cash and Equivalents125.21 M42.26 M36.43 M82.98 M112.67 M91.18 M
Cash and Equivalents USD125.21 M42.26 M36.43 M82.98 M112.67 M91.18 M
Total Debt31.78 M43.18 M136.07 M138.94 M269.93 M291.24 M
Debt Non Current31.78 M40.58 M131.45 M136.15 M255.07 M275.2 M
Total Debt USD31.78 M43.18 M136.07 M138.94 M269.93 M291.24 M
Deferred Revenue20.86 M23.06 M24.57 M87 M100.05 M107.95 M
Shareholders Equity109.84 M25.93 M(10.94 M)113.38 M243.86 M263.12 M
Shareholders Equity USD109.84 M25.93 M(10.94 M)113.38 M243.86 M263.12 M
Investments160.2 M156.47 M231.33 M418.03 M511.02 M551.37 M
Investments Current143.69 M156.47 M188.68 M381.07 M358.97 M387.31 M
Investments Non Current7.67 M16.52 M42.65 M36.95 M152.05 M164.05 M
Total Liabilities184.97 M185.24 M300.75 M420.42 M597.46 M644.62 M
Current Liabilities32.44 M22.19 M26.02 M31.2 M71.86 M77.53 M
Liabilities Non Current152.52 M163.05 M274.73 M389.22 M525.6 M567.09 M
Trade and Non Trade Payables5.25 M3.76 M8.16 M8.05 M21.09 M22.75 M
Property Plant and Equipment Net3.57 M3.5 M13.41 M16.27 M146.41 M157.97 M
Trade and Non Trade Receivables1.11 M2.23 M5.16 M4.42 M51.82 M55.91 M
Accumulated Retained Earnings Deficit(646.08 M)(743.32 M)(865.02 M)(992.31 M)(1.21 B)(1.24 B)

Be your own money manager

Our tools can tell you how much better you can do entering a position in Cytokinetics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Center Now

   

Portfolio Center

All portfolio management and optimization tools to improve performance of your portfolios
All  Next Launch Module

Pair Trading with Cytokinetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytokinetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytokinetics will appreciate offsetting losses from the drop in the long position's value.

Moving against Cytokinetics

0.66KZIAKazia Therapeutics Fiscal Year End 6th of October 2022 PairCorr
The ability to find closely correlated positions to Cytokinetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytokinetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytokinetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytokinetics to buy it.
The correlation of Cytokinetics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytokinetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytokinetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytokinetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Probability Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
4.8 B
Quarterly Revenue Growth YOY
30.29
Return On Assets
-0.17
Return On Equity
-3.38
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.